Wedge Capital Management L L P NC Sells 23,165 Shares of Ralliant Corporation $RAL

Wedge Capital Management L L P NC cut its stake in Ralliant Corporation (NYSE:RAL) by 39.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,123 shares of the company’s stock after selling 23,165 shares during the period. Wedge Capital Management L L P NC’s holdings in Ralliant were worth $1,580,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Dodge & Cox purchased a new stake in Ralliant in the 2nd quarter valued at about $523,571,000. Viking Global Investors LP bought a new stake in shares of Ralliant during the second quarter valued at approximately $257,200,000. State Street Corp bought a new stake in shares of Ralliant during the second quarter valued at approximately $213,096,000. Flossbach Von Storch SE purchased a new stake in shares of Ralliant in the second quarter valued at approximately $198,077,000. Finally, Norges Bank purchased a new stake in shares of Ralliant in the second quarter valued at approximately $108,453,000.

Ralliant Price Performance

Shares of RAL stock opened at $51.64 on Wednesday. The stock’s fifty day simple moving average is $47.14. Ralliant Corporation has a 1-year low of $40.70 and a 1-year high of $55.08. The stock has a market cap of $5.83 billion and a P/E ratio of 40.66. The company has a current ratio of 1.49, a quick ratio of 1.03 and a debt-to-equity ratio of 0.39.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.02. The business had revenue of $529.10 million during the quarter, compared to analysts’ expectations of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 23rd. Investors of record on Monday, December 8th were given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Ralliant’s dividend payout ratio (DPR) is presently 15.75%.

Wall Street Analyst Weigh In

Several research firms have commented on RAL. Royal Bank Of Canada raised their price objective on Ralliant from $45.00 to $52.00 and gave the stock a “sector perform” rating in a report on Friday, November 7th. Oppenheimer raised their price target on Ralliant from $55.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Truist Financial initiated coverage on Ralliant in a report on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective for the company. Citigroup raised shares of Ralliant from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $53.00 to $61.00 in a research note on Monday, December 8th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Ralliant in a research report on Monday, December 15th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $57.89.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.